Abstract: The COVID-19 outbreak of 2020 presents unprecedented challenges for the medical community. However, non-small cell lung cancer （NSCLC） research remains in full swing. Several of these important advances have led changes in clinical practice, such as the ADAURA study showing significant efficacy of third-generation EGFR- tyrosine kinase inhibitor in the adjuvant treatment of NSCLC patients, the Lung ART study concluding that conformal radiotherapy is not recommended as routine postoperative treatment for patients with completely resected stage ⅢA N2 NSCLC, MET inhibitors and RET inhibitors provide new precision therapies for patients with advanced NSCLC with relevant targets. In addition, there are important clinical research advances in targeted therapy and immunotherapy for both early and advanced NSCLC. It is foreseeable that in the next decade, there will be unprecedented therapeutic changes in NSCLC.